CNS Drugs

, Volume 27, Issue 3, pp 175–184 | Cite as

Treatment of Epileptic Encephalopathies

Therapy in Practice

Abstract

Epileptic encephalopathy is defined as a condition where the epileptic activity itself may contribute to the severe neurological and cognitive impairment seen, over and above that which would be expected from the underlying pathology alone. The epilepsy syndromes at high risk of this are a disparate group of conditions characterized by epileptic seizures that are difficult to treat and developmental delay. In this review, we discuss the ongoing debate regarding the significance of inter-ictal discharges and the impact of the seizures themselves on the cognitive delay or regression that is a common feature of these syndromes. The syndromes also differ in many ways and we provide a summary of the key features of the early-onset epileptic encephalopathies including Ohtahara and West syndromes in addition to later childhood-onset syndromes such as Lennox Gastaut and Doose syndromes. An understanding of the various severe epilepsy syndromes is vital to understanding the rationale for treatment. For example, the resolution of hypsarrhythmia in West syndrome is associated with an improvement in cognitive outcome and drives treatment choice, but the same cannot be applied to frequent inter-ictal discharges in Lennox Gastaut syndrome. We discuss the evidence base for treatment where it is available and describe current practice where it is not. For example, in West syndrome there is some evidence for preference of hormonal treatments over vigabatrin, although the choice and duration of hormonal treatment remains unclear. We describe the use of conventional and newer anti-epileptic medications in the various syndromes and discuss which medications should be avoided. Older possibly forgotten treatments such as sulthiame and potassium bromide also have a role in the severe epilepsies of childhood. We discuss hormonal treatment with particular focus on the treatment of West syndrome, continuous spike wave in slow wave sleep (CSWS)/electrical status epilepticus in slow wave sleep (ESES) and Landau Kleffner syndrome. The role of the ketogenic diet has in recent years come to the fore of the management of these severe epilepsies and we describe successful use in myoclonic astatic epilepsy, Lennox Gastaut syndrome and Dravet syndrome. It is important that resective epilepsy surgery is not ignored in the management of these children, particularly those with hemi-pathology who may present with ESES and respond well to hemispheric disconnection. Adjunctive and symptomatic surgical treatments such as vagal nerve stimulation and corpus callosotomy may improve seizure burden. Finally, it is vital that the identification and treatment of developmental, behavioural and psychiatric co-morbidities are not neglected and that a rational, holistic approach is taken to the management of epileptic encephalopathies.

References

  1. 1.
    Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009. Epilepsia. 2010;51(4):676–85.PubMedCrossRefGoogle Scholar
  2. 2.
    Nabbout R, Dulac O. Epilepsy: genetics of early-onset epilepsy with encephalopathy. Nat Rev Neurol. 2011;8(3):129–30.CrossRefGoogle Scholar
  3. 3.
    O’Callaghan FJ, Lux AL, Johnson AL, et al. The effect of lead time to treatment and of age of onset on developmental outcome at 4 years in infantile spasms: evidence from the United Kingdom Infantile Spasms Study. Epilepsia. 2011;52(7):1359–64.PubMedCrossRefGoogle Scholar
  4. 4.
    Primec ZR, Stare J, Neubauer D. The risk of lower mental outcome in infantile spasms increases after three weeks of hypsarrhythmia duration. Epilepsia. 2006;47(12):2202–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Kivity S, Lerman P, Shinnar S, et al. Long-term cognitive outcomes of a cohort of children with cryptogenic infantile spasms treated with high-dose adrenocorticotropic hormone. Epilepsia. 2004;45(3):255–62.PubMedCrossRefGoogle Scholar
  6. 6.
    Goh S, Kwiatkowski DJ, Thiele EA, et al. Infantile spasms and intellectual outcomes in children with tuberous sclerosis complex. Neurology. 2005;65(2):235–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Ohtahara S, Ishida T, Oka E. On the specific age dependent epileptic syndrome: the early-infantile epileptic encephalopathy with suppression-burst. No to Hattatsu. 1976;8:270–9.Google Scholar
  8. 8.
    Yamatogi Y, Ohtahara S. Early-infantile epileptic encephalopathy with suppression-bursts, Ohtahara syndrome; its overview referring to our 16 cases. Brain Dev. 2002;24(1):13–23.PubMedCrossRefGoogle Scholar
  9. 9.
    Saitsu H, Kato M, Tohyama J, et al. De novo mutations in the gene encoding STXBP1 (MUNC18-1) cause early infantile epileptic encephalopathy. Nat Genet. 2008;40(6):782–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Kato M, Saitoh S, Akasaka M, et al. A longer polyalanine expansion mutation in the ARX gene causes early infantile epileptic encephalopathy with suppression-burst pattern (Ohtahara syndrome). Am J Hum Genet. 2007;81(2):361–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Molinari F, Kaminska A, Plouin P, et al. Mutations in the mitochondrial glutamate carrier SLC25A22 in neonatal epileptic encephalopathy with suppression bursts. Clin Genet. 2009;76(2):188–94.PubMedCrossRefGoogle Scholar
  12. 12.
    Molinari F, Raas-Rothschild A, Palmieri L, et al. Impaired mitochondrial glutamate transport in autosomal recessive neonatal myoclonic epilepsy. Am J Hum Genet. 2005;76(2):334–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Carranza Rojo D, Hamiwka L, Suls A, et al. De novo SCN1A mutations in migrating partial seizures of infancy. Neurology. 2011;77(4):380–3.PubMedCrossRefGoogle Scholar
  14. 14.
    Poduri A, Chopra SS, Meyer E, et al. Homozygous PLCB1 deletion associated with malignant migrating partial seizures in infancy. Epilepsia. 2012;53(8):e146–50.PubMedCrossRefGoogle Scholar
  15. 15.
    Poduri A, Heinzen EL, Walsh CA, et al. Whole exome sequencing implicates SLC25A22 as a gene for MMPEI [abstract]. Epilepsia. 2011;52:16.CrossRefGoogle Scholar
  16. 16.
    Barcia G, Fleming MR, Nabbout R, et al. De novo gain-of-function KCNT1 channel mutations cause malignant migrating partial seizures of infancy. Nat Genet. 2012;44(11):1255–9.PubMedCrossRefGoogle Scholar
  17. 17.
    McTague A, Appleton R, Avula S, et al. Migrating partial seizures of infancy (MPSI): expansion of the electroclinical, radiological and pathological disease spectrum. Brain. 2013 (in press)Google Scholar
  18. 18.
    Guerrini R, Moro F, McShane MA, et al. Expansion of the first PolyA tract of ARX causes infantile spasms and status dystonicus. Neurology. 2007;69(5):427–33.PubMedCrossRefGoogle Scholar
  19. 19.
    Archer HL, Evans J, Osborne J, et al. CDKL5 mutations cause infantile spasms, early onset seizures, and severe mental retardation in female patients. J Med Genet. 2006;43(9):729–34.PubMedCrossRefGoogle Scholar
  20. 20.
    Auvin S, Lamblin MD, Bouvet-Mourcia A, et al. Infantile epileptic encephalopathy with late-onset spasms: report of 19 patients. Epilepsia. 2010;51(7):1290–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Claes L, Del-Favero J, Ceulemans B, et al. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet. 2001;68(6):1327–32.PubMedCrossRefGoogle Scholar
  22. 22.
    Depienne C, Bouteiller D, Poirier K, et al. Sporadic infantile epileptic encephalopathy caused by mutations in PCDH19 resembles Dravet syndrome but mainly affects females. PLoS Genet. 2009;5(2):e1000381.PubMedCrossRefGoogle Scholar
  23. 23.
    Arzimanoglou A, French J, Blume WT, et al. Lennox–Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol. 2009;8(1):82–93.PubMedCrossRefGoogle Scholar
  24. 24.
    Arzimanoglou A, Resnick T. All children who experience epileptic falls do not necessarily have Lennox–Gastaut syndrome … but many do. Epilept Disord. 2011;13(Suppl. 1):S3–13.Google Scholar
  25. 25.
    Hughes JR. A review of the relationships between Landau–Kleffner syndrome, electrical status epilepticus during sleep, and continuous spike-waves during sleep. Epilepsy Behav. 2011;20(2):247–53.PubMedCrossRefGoogle Scholar
  26. 26.
    Trivisano M, Specchio N, Cappelletti S, et al. Myoclonic astatic epilepsy: an age-dependent epileptic syndrome with favorable seizure outcome but variable cognitive evolution. Epilepsy Res. 2011;97(1–2):133–41.PubMedCrossRefGoogle Scholar
  27. 27.
    Kelley S, Kossoff E. Doose syndrome (myoclonic-astatic epilepsy): 40 years of progress. Dev Med Child Neurol. 2010;52(11):988–93.PubMedCrossRefGoogle Scholar
  28. 28.
    Kramer U, Chi CS, van Baalen A, et al. Febrile infection-related epilepsy syndrome (FIRES): pathogenesis, treatment, and outcome: a multicenter study on 77 children. Epilepsia. 2011;52(11):1956–65.PubMedCrossRefGoogle Scholar
  29. 29.
    Howell KB, Katanyuwong K, Mackay MT, et al. Long-term follow-up of febrile infection-related epilepsy syndrome. Epilepsia. 2012;53(1):101–10.PubMedCrossRefGoogle Scholar
  30. 30.
    Leen WG, Klepper J, Verbeek MM, et al. Glucose transporter-1 deficiency syndrome: the expanding clinical and genetic spectrum of a treatable disorder. Brain. 2010;133(3):655–70.PubMedCrossRefGoogle Scholar
  31. 31.
    Stockler S, Plecko B, van Karnebeek C, et al. Pyridoxine dependent epilepsy and antiquitin deficiency: clinical and molecular characteristics and recommendations for diagnosis, treatment and follow-up. Mol Genet Metab. 2011;104(1–2):48–60.PubMedCrossRefGoogle Scholar
  32. 32.
    Hoffmann GF, Schmitt B, Bagci S, et al. Pyridoxal 5′-phosphate may be curative in early-onset epileptic encephalopathy. J Inherit Metab Dis. 2007;30(1):96–9.PubMedCrossRefGoogle Scholar
  33. 33.
    National Institute for Clinical Excellence. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care [online]. Available from URL: http://www.nice.org.uk/cg137 [Accessed 2013 Jan 23].
  34. 34.
    Maguire M, Hemming K, Marson AG, et al. Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review. Epilepsia. 2010;51(12):2423–31.PubMedCrossRefGoogle Scholar
  35. 35.
    Wild JM, Chiron C, Perucca E, et al. Visual field loss in patients with refractory partial epilepsy treated with vigabatrin. CNS Drugs. 2009;23(11):965–82.PubMedCrossRefGoogle Scholar
  36. 36.
    Gaily E, Jonsson H, Lappi M. Visual fields at school-age in children treated with vigabatrin in infancy. Epilepsia. 2009;50(2):206–16.PubMedCrossRefGoogle Scholar
  37. 37.
    Glauser TA. Topiramate in the catastrophic epilepsies of childhood. J Child Neurol. 2000;15(Suppl. 1):S14–21.PubMedCrossRefGoogle Scholar
  38. 38.
    Coppola G, Capovilla G, Pascotto A, et al. Topiramate as add-on drug in severe myoclonic epilepsy in infancy: an Italian multicenter open trial. Epilepsy Res. 2002;49(1):45–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Chiron C, Marchand MC, Vincent J, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet. 2000;356(9242):1638–42.PubMedCrossRefGoogle Scholar
  40. 40.
    Glauser T, Kluger G, Arroyo S, et al. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology. 2008;70(21):1950–8.PubMedCrossRefGoogle Scholar
  41. 41.
    von Stulpnagel C, Coppola G, Kluger G, et al. First long-term experience with the orphan drug rufinamide in children with myoclonic-astatic epilepsy (Doose syndrome). Eur J Paediatr Neurol. 2012;16(5):459–63.CrossRefGoogle Scholar
  42. 42.
    Fejerman N, Caraballo R, Amartino H, et al. Sulthiame add-on therapy in children with focal epilepsies associated with encephalopathy related to electrical status epilepticus during slow sleep (ESES). Epilepsia. 2012;53(7):1156–61.PubMedCrossRefGoogle Scholar
  43. 43.
    Zupanc ML, Roell Werner R, Hecox KE, et al. Efficacy of felbamate in the treatment of intractable pediatric epilepsy. Pediatr Neurol. 2010;42(6):396–403.PubMedCrossRefGoogle Scholar
  44. 44.
    Okuda K, Yasuhara A, Kobayashi Y, et al. Successful control with bromide of two patients with malignant migrating partial seizures in infancy. Brain Dev. 2000;22(1):56–9.PubMedCrossRefGoogle Scholar
  45. 45.
    Lotte J, Haberlandt E, Kluger GJ, et al. Bromide in patients with SCN1A-mutations manifesting as Dravet syndrome. Neuropediatrics. 2012;43(1):17–21.PubMedCrossRefGoogle Scholar
  46. 46.
    Verhelst H, Boon P, Meirleir LD, et al. Steroids in intractable childhood epilepsy: clinical experience and review of the literature. Seizure. 2005;14(6):412–21.PubMedCrossRefGoogle Scholar
  47. 47.
    Gayatri NA, Ferrie CD, Cross H. Corticosteroids including ACTH for childhood epilepsy other than epileptic spasms. Cochrane Database Syst Rev. 2007;24(1):CD005222.Google Scholar
  48. 48.
    Lux AL, Edwards SW, Newton RW, et al. The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial. Lancet Neurol. 2005;4(11):712–7.PubMedCrossRefGoogle Scholar
  49. 49.
    Veggiotti P, Pera MC, Tassinari CA, et al. Therapy of encephalopathy with status epilepticus during sleep (ESES/CSWS syndrome): an update. Epilept Disord. 2012;14(1):1–11.Google Scholar
  50. 50.
    Buzatu M, Bulteau C, Van Bogaert P, et al. Corticosteroids as treatment of epileptic syndromes with continuous spike-waves during slow-wave sleep. Epilepsia. 2009;50(7):68–72.PubMedCrossRefGoogle Scholar
  51. 51.
    Neal EG, Chaffe H, Fitzsimmons G, et al. The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial. Lancet Neurol. 2008;7(6):500–6.PubMedCrossRefGoogle Scholar
  52. 52.
    Caraballo RH, Cersosimo RO, Fejerman N, et al. Ketogenic diet in patients with myoclonic-astatic epilepsy. Epilept Disord. 2006;8(2):151–5.Google Scholar
  53. 53.
    Kossoff E. The fat is in the fire: ketogenic diet for refractory status epilepticus. Epilepsy Curr. 2011;11(3):88–9.PubMedCrossRefGoogle Scholar
  54. 54.
    Lemmon ME, Terao NN, Kossoff EH, et al. Efficacy of the ketogenic diet in Lennox–Gastaut syndrome: a retrospective review of one institution’s experience and summary of the literature. Dev Med Child Neurol. 2012;54(5):464–8.PubMedCrossRefGoogle Scholar
  55. 55.
    Caraballo RH. Nonpharmacologic treatments of Dravet syndrome: focus on the ketogenic diet. Epilepsia. 2011;52(Suppl. 2):79–82.PubMedCrossRefGoogle Scholar
  56. 56.
    Wyllie E, Lachhwani DK, Worley S, et al. Successful surgery for epilepsy due to early brain lesions despite generalized EEG findings. Neurology. 2007;69(4):389–97.PubMedCrossRefGoogle Scholar
  57. 57.
    Asarnow RF, LoPresti C, Shields WD, et al. Developmental outcomes in children receiving resection surgery for medically intractable infantile spasms. Dev Med Child Neurol. 1997;39(7):430–40.PubMedCrossRefGoogle Scholar
  58. 58.
    Peltola ME, Liukkonen E, Valanne L, et al. The effect of surgery in encephalopathy with electrical status epilepticus during sleep. Epilepsia. 2011;52(3):602–9.PubMedCrossRefGoogle Scholar
  59. 59.
    Cross JH, Neville BG. The surgical treatment of Landau–Kleffner syndrome. Epilepsia. 2009;50(S7):63–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  1. 1.Neurosciences UnitUCL-Institute of Child HealthLondonUK
  2. 2.Department of NeurologyGreat Ormond Street HospitalLondonUK
  3. 3.Young EpilepsySurreyUK

Personalised recommendations